Marquet Magda 4

4 · ANAPTYSBIO, INC · Filed Jan 16, 2026

Form 4

Period: 2026-01-15

Director

Transactions

Exercise/Conversion
Common Stock
2026-01-15$26.11/sh+11,000$287,210→ 20,930 total
Sale
Common Stock
[F1]
2026-01-15$48.12/sh−9,290$446,999→ 11,640 total
Sale
Common Stock
[F2]
2026-01-15$48.85/sh−1,710$83,532→ 9,930 total
Exercise/Conversion
Stock Option (right to buy)
[F3][F4]
2026-01-15−11,000→ 0 total
Exercise: $26.11Exp: 2031-01-17→ Common Stock (11,000 underlying)

Footnotes (4)

[F1]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.595 to $48.54 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.625 to $48.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The stock option is fully vested.
[F4]In addition to the options to purchase shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 70,104 shares of common stock, which options vest according to their terms.

Signature

/s/ Eric Loumeau, Attorney-in-Fact|2026-01-16

Documents

1 file